INCA33890 (TGFβR2×PD-1–Targeted Bispecific Antibody)[1,2]

Population: patients with advanced or metastatic solid tumors

Phase 1
ClinicalTrials.gov ID: NCT05836324
Study ID: INCA33890-101

Adults with advanced or metastatic solid tumors

N≈408

Part 1

INCA33890 monotherapy

Part 1a: Dose escalation[a]

RDE(s)

Part 1b: Dose expansion[a]

- ICI-sensitive tumors
- ICI-nonsensitive tumors

Part 2

INCA33890 combinations in MSS CRC

- Bevacizumab
- Bevacizumab + FOLFIRI
- Bevacizumab + FOLFOX
- Cetuximab

Part 2a: Dose escalation[a,b]

RDE(s)

Part 2b: Dose expansion[a,b]

[a] INCA33890 will be administered at the protocol-defined dose based on cohort assignment. [b] Bevacizumab, FOLFIRI, FOLFOX, and cetuximab will be administered at the protocol-defined doses.

PRIMARY ENDPOINTS

Dose-limiting toxicities

Incidence of TEAEs

Incidence of TEAEs leading to dose modification or discontinuation

SECONDARY ENDPOINTS

ORR

DCR

DOR

PK parameters

SELECT INCLUSION CRITERIA

- ≥18 years of age
- Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol
- Part 1: disease progression after receiving available therapies or were intolerant, ineligible, or declined standard treatment
- Part 2: depending on cohort, prior treatment for the malignancy under study may or may not be required
- Measurable disease per RECIST version 1.1
- ECOG PS of 0 or 1

SELECT EXCLUSION CRITERIA

- Additional malignancy progressing on or requiring active treatment, or history of other malignancy within 2 years
- Active autoimmune disease requiring corticosteroids
- Significant concurrent, uncontrolled medical condition
- Active HBV, active HCV, or HIV positive
- Not recovered to grade ≤1 or baseline from residual toxicities of prior therapy
- Chronic or current infections requiring systemic treatment

The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the uses under investigation.

For more information, visit **IncyteClinicalTrials.com** or contact us at **1-855-4MED-INFO (855-463-3463)** or **clintrials@incyte.com**

A copy of this panel can be accessed using the QR code:

CRC, colorectal cancer; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, leucovorin calcium, fluorouracil, and irinotecan hydrochloride; FOLFOX, leucovorin calcium, fluorouracil, and oxaliplatin; HBV, hepatitis B virus; HCV, hepatitis C virus; ICI, immune checkpoint inhibitor; MSS, microsatellite stable; ORR, objective response rate; PD-1, programmed cell death 1 protein; PK, pharmacokinetics; RDE, recommended dose for expansion; RECIST, Response Evaluation Criteria in Solid Tumors; TEAE, treatment-emergent adverse event; TGFβR2, transforming growth factor β receptor 2.

1. ClinicalTrials.gov. Accessed Mar 2026. https://clinicaltrials.gov/study/NCT05836324 2. Data on file. Incyte Corporation.

This information is current as of March 3, 2026.